Vericel to Host Second-Quarter 2017 Earnings Webcast and Conference Call on August 9, 2017
CAMBRIDGE, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call:
| What: | Vericel Corporation Second-Quarter 2017 Earnings Call |
| When: | Wednesday, August 9, 2017 at 8:00am (EDT) |
| Where: | http://investors.vcel.com/events.cfm |
| How: | The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events.cfm. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. |
| |
To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation second-quarter 2017 investor conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events.cfm until August 9, 2018. A replay of the call will also be available until 11:00am (EDT) on August 13, 2017 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 54878623.
About Vericel Corporation
Vericel develops, manufactures, and markets autologous expanded cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is developing ixmyelocel-T, an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at www.vcel.com.
Epicel®, Carticel®, and MACI® are registered trademarks of Vericel Corporation. © 2017 Vericel Corporation. All rights reserved.
Global Media Contacts: David Schull Russo Partners LLC +1 212-845-4271 (office) +1 858-717-2310 (mobile) David.schull@russopartnersllc.com Karen Chase Russo Partners LLC +1 646-942-5627 (office) +1 917-547-0434 (mobile) Karen.chase@russopartnersllc.com Investor Contacts: Chad Rubin The Trout Group crubin@troutgroup.com +1 (646) 378-2947 Lee Stern The Trout Group lstern@troutgroup.com +1 (646) 378-2922
